StockDuty ← Dashboard Aug 07, 2026 08:51 AM ET
CatalystFDA/Bio

Revolution Q2 Net Loss Widens; Plans Phase 3 Study Of Elironrasib In Q4; Wedbush Lifts Price Target

Revolution Q2 Net Loss Widens; Plans Phase 3 Study Of Elironrasib In Q4; Wedbush Lifts Price Target

Sources